Discover
LBRX
LB Pharmaceuticals Inc
37.22
2 x 32.42
2 x 57.43
bid
ask
+
2.61
7.54%
2 @ 04:01 PM
37.22 +0.00 (0.00%)
| Ytd | 67.21% | |
| 1y | 137.98% |
35.01
day range
38.50
14.61
52 week range
49.48
| Open | 35.01 | Prev Close | 34.61 | Low | 35.01 | High | 38.50 | Mkt Cap | 1.20B |
| Vol | 642.58K | Avg Vol | 344.34K | EPS | 0.10 | P/E | 372.20 | Forward P/E | -7.25 |
| Beta | N/A | Short Ratio | 20.99 | Inst. Own | 102.44% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 43.75 | 200-d Avg | 31.19 | 1yr Est | 58.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-05 | 2026-09 | -1.62 | N/A | N/A | N/A |
| 2026-08-11 | 2026-06 | -0.8 | -1.71 | -0.91 | -112.78% |
| 2026-05-12 | 2026-03 | -0.75 | -0.67 | 0.08 | 10.67% |
| 2026-03-26 | 2025-12 | -0.45 | -0.45 | N/A | N/A |
| 2025-11-06 | 2025-09 | -0.57 | -0.61 | -0.04 | -7.02% |
| 2025-09-08 | 2025-06 | 0 | -1.44 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-09 | Canaccord Genuity | Upgrade | Buy | |
| 2026-10-06 | Guggenheim | Upgrade | Buy | |
| 2026-10-05 | Roth Capital | Downgrade | Buy | Neutral |
| 2026-10-02 | Needham | Upgrade | Buy | |
| 2026-08-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-08-12 | BMO Capital | Upgrade | Outperform | Outperform |
Profile
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-09-11 | DEEP TRACK BIOTECHNOLOGY MASTER FUND LTD | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | NUSSBAUM RAN | Director | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2025-09-11 | VIDA VENTURES GP III, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Deep Track Capital, Lp | 3.35M | 124.79M | 10.39% |
| 2026-06-29 | Blackrock Inc. | 2.73M | 101.77M | 8.48% |
| 2026-06-29 | RA Capital Management, L.P. | 2.21M | 82.20M | 6.85% |
| 2026-06-29 | Trails Edge Capital Partners, LP | 1.52M | 56.69M | 4.72% |
| 2026-06-29 | Commodore Capital Lp | 1.50M | 55.83M | 4.65% |
| 2026-06-29 | JPMORGAN CHASE & CO | 1.50M | 55.73M | 4.64% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 692.91K | 25.79M | 2.15% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 672.00K | 25.01M | 2.08% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 573.04K | 21.33M | 1.78% |
| 2026-05-30 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 567.63K | 21.13M | 1.76% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 278.89K | 10.38M | 0.86% |
| 2026-07-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 244.91K | 9.12M | 0.76% |